Skip to content

Eloxx Pharmaceuticals, Inc.: current accounts payable

Eloxx Pharmaceuticals current accounts payable: $2.71 million at 2025-12-31, down 49.3% on the year. 17 values since 2011, each linked to its SEC filing.

All Eloxx Pharmaceuticals, Inc. financial histories

At a glance

Eloxx Pharmaceuticals reported current accounts payable of $2.71 million at 2025-12-31, down 49.3% from $5.35 million a year earlier. From 2011 to 2025 it grew at a compound 11.5% a year, from $559.5 thousand to $2.71 million. Across the last five reported years it ranged from $1.38 million (2021-12-31) to $5.70 million (2023-12-31). That was 51.5% of total assets ($5.27 million) at the same date.

Computed from the values in the table below, in USD; each links to the filing it came from.

What this measure means

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Exact concept: us-gaap:AccountsPayableCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2011-06-30 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Current accounts payable in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
-2025-12-312,713,000USD2026-03-1710-K · 0001193125-26-108687 SEC
-2024-12-315,346,000USD2026-03-1710-K · 0001193125-26-108687 SEC
-2023-12-315,699,000USD2026-03-1710-K · 0001193125-26-108687 SEC
-2022-12-313,020,000USD2023-03-3110-K · 0000950170-23-011360 SEC
-2021-12-311,379,000USD2023-03-3110-K · 0000950170-23-011360 SEC
-2020-12-31481,000USD2022-03-3010-K · 0001564590-22-012683 SEC
-2019-12-311,871,000USD2021-03-1210-K · 0001564590-21-012703 SEC
-2018-12-31747,000USD2020-03-0610-K · 0001564590-20-009148 SEC
-2017-12-311,530,000USD2019-03-1410-K · 0001564590-19-007811 SEC
-2017-06-30191,597USD2017-10-1310-K · 0001144204-17-052475 SEC
-2016-12-311,899,000USD2018-03-1610-K · 0001193125-18-086028 SEC
-2016-06-3090,305USD2017-10-1310-K · 0001144204-17-052475 SEC
-2015-06-30232,033USD2016-10-1310-K · 0001144204-16-128038 SEC
-2014-06-30901,180USD2015-10-0910-K · 0001144204-15-058919 SEC
-2013-06-30637,320USD2014-09-2910-K · 0001144204-14-058176 SEC
-2012-06-30594,514USD2013-09-1110-K · 0001144204-13-050259 SEC
-2011-06-30559,525USD2012-10-2610-K/A · 0001144204-12-057875 SEC

Related ELOXX PHARMACEUTICALS, INC. histories

All 53 Eloxx Pharmaceuticals histories

Inspect the source

Entity
ELOXX PHARMACEUTICALS, INC. / CIK 0001035354
Captured
SEC response SHA-256
b351a9ed06ee3e6f1d738bbdb3852b866526fe561e11a7ffd4a81bc43bb27195

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001035354.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))